Research - Page 8 of 10 - Fideres

Australian Gas: Are Further Market Troubles Ahead?

Key Points The Australian Competition and Consumer Commission (ACCC) has recently released two inquiry reports on the Eastern Australian Natural

October 17, 2017

CDOR Under Pressure: Canada’s Rate Benchmark in Trouble

Key Points Between September 2007 and September 2009, the Canadian Dollar Offered Rate (CDOR) was potentially suppressed by 30 –

October 9, 2017

Indexing in Disguise: Closet Trackers Under Fire in Europe

Key Points Fideres has found over 16% of European UCITs funds of the sample analyzed show characteristics that may indicate

February 13, 2017

What Pharmacy Benefit Managers Don’t Want You to Know

Key Points Payment flow and pricing structure are highly complex and nontransparent within the US pharmaceutical industry. No single entity

February 10, 2017

Generic Drug Prices: Why U.S. Costs Keep Rising

Key Points Generic drug price increases may be more widespread than the scope of any current lawsuit. Fideres has identified

January 13, 2017

Twombly Or Not Twombly?

Key Points We assess the impact of the Twombly decision on US antitrust class actions. The number of filings has

October 7, 2016

Drug Cartels In The USA

Key Points Significant price spikes in generic drugs have led to increased scrutiny from lawmakers. Fideres has conducted detailed analysis

August 28, 2016

Indexers in Hiding: Active Funds That Aren’t So Active

Key Points Active share alone can give a biased view of funds’ activeness. Other metrics must be considered alongside active

Event Studies: A Legal Tool with Hidden Pitfalls

Key Points When relying on event studies in 10b5 securities litigation cases, law firms should consider a number of issues when